How M.B.B.S. was paid
$2.2M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Robert Ang, M.B.B.S.Former President and Chief Executive Officer | $620,945 | $361,500 | $864,800 | $341,520 | $31,584 | $2,220,349 |
| Eyal Attar, M.D.Former Chief Medical Officer | $487,100 | $150,625 | $230,000 | $195,303 | $12,757 | $1,075,785 |
| Tirtha Chakraborty, Ph.D.Former Chief Scientific Officer and Head of Technical Operations | $477,200 | $129,538 | $197,800 | $190,379 | $8,935 | $1,003,852 |
What changed and why
- $2.2M$2,220,349: CEO total compensation in 2024, down from $2,691,044 in 2023.
- 100%100%: Board-determined overall attainment of 2024 corporate objectives.
- 55%55%: CEO target performance bonus based on 2024 base salary.
- 40%40%: Target performance bonus for the Chief Medical Officer and Chief Scientific Officer.
- 2024: Executive equity awards comprised a mix of stock options and RSUs.
- $1.34$1.34: Reduced exercise price under the February 2025 stock option repricing.
Other Vor Biopharma proxy statements
- 2026 proxy statement
Jean-Paul Kress paid $65M.
Filed Apr 27, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.